5 Key Takeaways

• 1

  CRISPR therapy renizgamglogene autogedtemcel effectively raised fetal hemoglobin in patients with severe sickle cell disease.

• 2

  In a phase 1-2 study, total hemoglobin increased from 9.8 g/dL to 13.8 g/dL within six months after treatment.

• 3

  Fetal hemoglobin levels rose significantly from 2.5% to 48.1%, with F-cell levels exceeding 99% by month six.

• 4

  Twenty-seven out of 28 patients experienced no severe vaso-occlusive events post-infusion, indicating clinical effectiveness.

• 5

  The therapy demonstrated robust engraftment, with neutrophil and platelet recovery occurring within 23 and 25 days, respectively.